1. Home
  2. JMSB vs CAPR Comparison

JMSB vs CAPR Comparison

Compare JMSB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JMSB
  • CAPR
  • Stock Information
  • Founded
  • JMSB 2005
  • CAPR 2005
  • Country
  • JMSB United States
  • CAPR United States
  • Employees
  • JMSB N/A
  • CAPR N/A
  • Industry
  • JMSB Major Banks
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JMSB Finance
  • CAPR Health Care
  • Exchange
  • JMSB Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • JMSB 282.0M
  • CAPR 322.7M
  • IPO Year
  • JMSB N/A
  • CAPR N/A
  • Fundamental
  • Price
  • JMSB $18.99
  • CAPR $7.96
  • Analyst Decision
  • JMSB Buy
  • CAPR Strong Buy
  • Analyst Count
  • JMSB 2
  • CAPR 8
  • Target Price
  • JMSB $22.50
  • CAPR $24.75
  • AVG Volume (30 Days)
  • JMSB 15.4K
  • CAPR 1.9M
  • Earning Date
  • JMSB 07-23-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • JMSB 1.58%
  • CAPR N/A
  • EPS Growth
  • JMSB 688.28
  • CAPR N/A
  • EPS
  • JMSB 1.32
  • CAPR N/A
  • Revenue
  • JMSB $56,750,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • JMSB N/A
  • CAPR $16.24
  • Revenue Next Year
  • JMSB N/A
  • CAPR $328.11
  • P/E Ratio
  • JMSB $14.39
  • CAPR N/A
  • Revenue Growth
  • JMSB 59.00
  • CAPR N/A
  • 52 Week Low
  • JMSB $13.81
  • CAPR $3.84
  • 52 Week High
  • JMSB $26.52
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • JMSB 50.78
  • CAPR 48.47
  • Support Level
  • JMSB $18.85
  • CAPR $7.60
  • Resistance Level
  • JMSB $19.75
  • CAPR $8.60
  • Average True Range (ATR)
  • JMSB 0.44
  • CAPR 0.64
  • MACD
  • JMSB 0.02
  • CAPR 0.15
  • Stochastic Oscillator
  • JMSB 56.07
  • CAPR 47.87

About JMSB John Marshall Bancorp Inc.

John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: